Kyntra Bio appoints Singer and Kyntra Bio stock matches EUR 5.63 prior close

Published on 10/05/2026 at 11:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kyntra Bio stock costs EUR 5.63 on October 5, 2026 after EUR 5.63. Second-quarter 2026 revenue was negative USD 1.47 million versus USD 2.05 million.

KYNB, US31572Q8814, Illustration mit AI erstellt.

Kyntra Bio (ISIN US31572Q8814) was trading at EUR 5.63 at Lang & Schwarz on October 5, 2026 at 11:32 a.m. CEST, unchanged at 0.00 percent versus the EUR 5.63 prior close on October 2, 2026. GlobeNewswire reported on October 1, 2026 that the company appointed Andrew E. Singer as an independent director and Audit Committee member, effective the same date.

Singer brings biotechnology finance experience

Singer has more than 25 years of experience in investment banking, corporate strategy, business development and public-company leadership, according to the company announcement. Maykin Ho stepped down from the board effective September 30, 2026 after nearly eight years, making the appointment a broader governance change rather than a routine addition.

The timing places the board change alongside a sharply more optimistic external valuation view. Fintel reported on September 17, 2026 that Lake Street initiated coverage with a Buy rating and a USD 41.00 price target.

Second-quarter revenue remains the counterweight

The latest operating figures show why the target depends on pipeline execution. Fintel said Kyntra Bio reported negative USD 1.47 million in revenue for the second quarter of 2026, compared with USD 2.05 million in consensus revenue. The gap is a direct reminder that the company is being valued primarily on development prospects rather than recurring commercial sales.

Makkler reported that second-quarter 2026 net income reached USD 12.0 million and highlighted ongoing clinical work involving FG-3246 and roxadustat. The combination of negative revenue and positive net income points to the importance of non-operating items and milestone-related developments in interpreting the quarter.

Stock holds the prior-close level

Kyntra Bio stock was trading at EUR 5.63 at Lang & Schwarz on October 5, 2026 at 11:32 a.m. CEST, unchanged at 0.00 percent versus the EUR 5.63 prior close on October 2, 2026. The primary Nasdaq listing was last at USD 6.31 on October 2, 2026 at 4:00 p.m. ET, while the 52-week range was USD 6.30 to USD 12.13 and market capitalization was USD 25.5 million as of that quote. TradingView lists November 9, 2026 as the next earnings date.